Voinea I, Petrova E, Dumitru N, Cocolos A, Ioachim D, Goldstein A
J Clin Med. 2024; 13(23).
PMID: 39685621
PMC: 11641973.
DOI: 10.3390/jcm13237161.
Shi D, Yao M, Wu D, Jiang M, Li J, Zheng Y
Diagn Pathol. 2024; 19(1):146.
PMID: 39548512
PMC: 11566394.
DOI: 10.1186/s13000-024-01573-3.
Stanescu L, Ghemigian A, Ciobica M, Nistor C, Ciuche A, Radu A
Int J Mol Sci. 2024; 25(18).
PMID: 39337252
PMC: 11431960.
DOI: 10.3390/ijms25189765.
Toth L, Mokanszki A, Mehes G
Pathol Oncol Res. 2024; 30:1611733.
PMID: 38953007
PMC: 11215025.
DOI: 10.3389/pore.2024.1611733.
Desilets A, Repetto M, Yang S, Sherman E, Drilon A
Cancers (Basel). 2023; 15(16).
PMID: 37627175
PMC: 10452615.
DOI: 10.3390/cancers15164146.
Challenges in the care of patients with RET-altered thyroid cancer: a multicountry mixed-methods study.
Murray S, Subbiah V, Sherman S, Peloquin S, Sireci A, Grohe C
Thyroid Res. 2023; 16(1):22.
PMID: 37574538
PMC: 10424354.
DOI: 10.1186/s13044-023-00166-4.
Personalized Medicine in Medullary Thyroid Carcinoma: A Broad Review of Emerging Treatments.
Martins R, Jesus T, Cardoso L, Soares P, Vinagre J
J Pers Med. 2023; 13(7).
PMID: 37511745
PMC: 10381735.
DOI: 10.3390/jpm13071132.
Precision oncology with selective RET inhibitor selpercatinib in -rearranged cancers.
Gouda M, Subbiah V
Ther Adv Med Oncol. 2023; 15:17588359231177015.
PMID: 37360768
PMC: 10288430.
DOI: 10.1177/17588359231177015.
Approach to risk stratification for papillary thyroid carcinoma based on molecular profiling: institutional analysis.
Staubitz J, Muller C, Heymans A, Merten C, Roos B, Poplawski A
BJS Open. 2023; 7(3).
PMID: 37146205
PMC: 10162683.
DOI: 10.1093/bjsopen/zrad029.
Tumor-Agnostic Precision Medicine from the AACR GENIE Database: Clinical Implications.
Gouda M, Nelson B, Buschhorn L, Wahida A, Subbiah V
Clin Cancer Res. 2023; 29(15):2753-2760.
PMID: 37061987
PMC: 10390861.
DOI: 10.1158/1078-0432.CCR-23-0090.
Adefovir Dipivoxil as a Therapeutic Candidate for Medullary Thyroid Carcinoma: Targeting RET and STAT3 Proto-Oncogenes.
Alqahtani T, Kumarasamy V, Alghamdi S, Suliman R, Bin Saleh K, Alrashed M
Cancers (Basel). 2023; 15(7).
PMID: 37046823
PMC: 10093259.
DOI: 10.3390/cancers15072163.
RET aberrant cancers and RET inhibitor therapies: Current state-of-the-art and future perspectives.
Addeo A, Miranda-Morales E, den Hollander P, Friedlaender A, Sintim H, Wu J
Pharmacol Ther. 2023; 242:108344.
PMID: 36632846
PMC: 10141525.
DOI: 10.1016/j.pharmthera.2023.108344.
Precious Gene: The Application of RET-Altered Inhibitors.
Gou Q, Gan X, Li L, Gou Q, Zhang T
Molecules. 2022; 27(24).
PMID: 36557971
PMC: 9784389.
DOI: 10.3390/molecules27248839.
Clinicopathologic characteristics and diagnostic methods of rearrangement in Chinese non-small cell lung cancer patients.
Feng J, Li Y, Wei B, Guo L, Li W, Xia Q
Transl Lung Cancer Res. 2022; 11(4):617-631.
PMID: 35529790
PMC: 9073740.
DOI: 10.21037/tlcr-22-202.
Investigating natural compounds against oncogenic RET tyrosine kinase using pharmacoinformatic approaches for cancer therapeutics.
Parate S, Kumar V, Hong J, Lee K
RSC Adv. 2022; 12(2):1194-1207.
PMID: 35425116
PMC: 8978841.
DOI: 10.1039/d1ra07328a.
Hallmarks of RET and Co-occuring Genomic Alterations in -aberrant Cancers.
Adashek J, Desai A, Andreev-Drakhlin A, Roszik J, Cote G, Subbiah V
Mol Cancer Ther. 2021; 20(10):1769-1776.
PMID: 34493590
PMC: 8492504.
DOI: 10.1158/1535-7163.MCT-21-0329.
Precision therapy for RET-altered cancers with RET inhibitors.
Thein K, Velcheti V, Mooers B, Wu J, Subbiah V
Trends Cancer. 2021; 7(12):1074-1088.
PMID: 34391699
PMC: 8599646.
DOI: 10.1016/j.trecan.2021.07.003.
The importance of the RET gene in thyroid cancer and therapeutic implications.
Salvatore D, Santoro M, Schlumberger M
Nat Rev Endocrinol. 2021; 17(5):296-306.
PMID: 33603219
DOI: 10.1038/s41574-021-00470-9.
Genomics and Epigenomics of Medullary Thyroid Carcinoma: From Sporadic Disease to Familial Manifestations.
Barletta J, Nose V, Sadow P
Endocr Pathol. 2021; 32(1):35-43.
PMID: 33492588
PMC: 9353617.
DOI: 10.1007/s12022-021-09664-3.
Genetic Landscape of Papillary Thyroid Carcinoma and Nuclear Architecture: An Overview Comparing Pediatric and Adult Populations.
Rangel-Pozzo A, Sisdelli L, Cordioli M, Vaisman F, Caria P, Mai S
Cancers (Basel). 2020; 12(11).
PMID: 33120984
PMC: 7693829.
DOI: 10.3390/cancers12113146.